Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225857 | 0.86 | HDAC1 (0.55) | CHEK1PTGDR2HDAC1HDAC8HDAC6 | |
| SCHEMBL29944217 | 0.86 | HTR2C (0.63) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL3543198 | 0.86 | HTR2C (0.63) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL3547467 | 0.86 | HTR2C (0.63) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL17953075 | 0.85 | PTGDR2 (0.54) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL25230843 | 0.84 | CHEK1 (0.45) | CHEK1PTGDR2SIGMAR1HTR2C | |
| SCHEMBL22221788 | 0.84 | PTGDR2 (0.53) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL22221831 | 0.83 | PTGDR2 (0.52) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL22221724 | 0.82 | PTGDR2 (0.53) | PTGDR2HDAC1HDAC8HDAC6HTR2C | |
| SCHEMBL22221696 | 0.81 | DRD2 (0.64) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220055997-A1 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS COMPRISING SAME | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-02-24 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | CHEK1 1050/4885PTGDR2 1147/4885HDAC1 1440/4885 |
| US-20220055997-A1 | ANTIMICROBIAL COMPOUNDS AND COMPOSITIONS COMPRISING SAME | MPO, IMMT, CLPP | CHEK1 3919/4885PTGDR2 4624/4885HDAC1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.